Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease (‘CTAD’) 2024 Conference
- Two posters were presented by Annovis’ President and CEO, Dr. Maria Maccecchini, focusing on the company’s lead drug candidate buntanetap and its performance in clinical trials for the treatment of Alzheimer’s disease (“AD”).
- A leading event for the Alzheimer’s research community, CTAD 2024, brought together key members of pharmaceutical companies, academic research centers, and patient advocacy groups to discuss avenues for AD treatment.
- Buntanetap has been shown to significantly improve cognition in early AD patients, both ApoE4 carriers and non-carriers, and normalize biomarkers associated with AD pathology.
- The company is preparing for Phase 3 clinical trials for buntanetap in early-stage Alzheimer’s patients: a 6-month study to confirm symptomatic benefits and an 18-month study to explore disease-modifying effects.
Annovis (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), presented two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference (https://nnw.fm/vhc88 ), held between Oct. 29 and Nov. 1 in Marid, Spain.
The posters are now available online on Annovis’ website.
Key Findings Presented:
Poster: “Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer’s Patients.”
The Phase 2/3 AD clinical study involved 353 patients and assessed buntanetap’s efficacy and safety on top of standard medications. The data showed that buntanetap significantly improved cognition in patients with early AD by 3.3 points on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group. The data was consistent with previous phase 2 AD/PD (NCT04524351) and DISCOVER (NCT02925650) studies.
Poster: “Biomarker Data Showed Buntanetap Reduced Neurotoxic Proteins, Improved Axonal Integrity, Reduced Inflammation, and Neuronal Functions in Alzheimer’s Clinical Studies.”
Combined biomarker data from clinical studies in AD and PD patients showed that buntanetap reduced multiple neurotoxic aggregating proteins, reduced inflammation and preserved neuronal functions. Altogether, these biomarkers data, measured in plasma and in cerebrospinal fluid (“CSF”), support buntanetap’s clinical efficacy in improving AD patients’ cognitive function.
Following encouraging clinical trial results, the company was cleared by the U.S. Food and Drug Administration (“FDA”) to pursue Phase 3 clinical trials for buntanetap in early-stage Alzheimer’s patients and agreed on the next steps to advance toward a New Drug Application (“NDA”) submission. As part of the Phase 3 program, the company will hold two studies: a 6-month study, set to begin in Q1 2025, to confirm buntanetap’s symptomatic benefits and an 18-month study to explore potential disease-modifying effects.
For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Two posters were presented by Annovis’ President and CEO, Dr. Maria Maccecchini, focusing on the company’s lead drug candidate buntanetap and its performance in clinical trials for the treatment of Alzheimer’s disease (“AD”).
- A leading event for the Alzheimer’s research community, CTAD 2024, brought together key members of pharmaceutical companies, academic research centers, and patient advocacy groups to discuss avenues for AD treatment.
- Buntanetap has been shown to significantly improve cognition in early AD patients, both ApoE4 carriers and non-carriers, and normalize biomarkers associated with AD pathology.
- The company is preparing for Phase 3 clinical trials for buntanetap in early-stage Alzheimer’s patients: a 6-month study to confirm symptomatic benefits and an 18-month study to explore disease-modifying effects.
Annovis (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), presented two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference (https://nnw.fm/vhc88 ), held between Oct. 29 and Nov. 1 in Marid, Spain.
The posters are now available online on Annovis’ website.
Key Findings Presented:
Poster: “Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer’s Patients.”
The Phase 2/3 AD clinical study involved 353 patients and assessed buntanetap’s efficacy and safety on top of standard medications. The data showed that buntanetap significantly improved cognition in patients with early AD by 3.3 points on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group. The data was consistent with previous phase 2 AD/PD (NCT04524351) and DISCOVER (NCT02925650) studies.
Poster: “Biomarker Data Showed Buntanetap Reduced Neurotoxic Proteins, Improved Axonal Integrity, Reduced Inflammation, and Neuronal Functions in Alzheimer’s Clinical Studies.”
Combined biomarker data from clinical studies in AD and PD patients showed that buntanetap reduced multiple neurotoxic aggregating proteins, reduced inflammation and preserved neuronal functions. Altogether, these biomarkers data, measured in plasma and in cerebrospinal fluid (“CSF”), support buntanetap’s clinical efficacy in improving AD patients’ cognitive function.
Following encouraging clinical trial results, the company was cleared by the U.S. Food and Drug Administration (“FDA”) to pursue Phase 3 clinical trials for buntanetap in early-stage Alzheimer’s patients and agreed on the next steps to advance toward a New Drug Application (“NDA”) submission. As part of the Phase 3 program, the company will hold two studies: a 6-month study, set to begin in Q1 2025, to confirm buntanetap’s symptomatic benefits and an 18-month study to explore potential disease-modifying effects.
For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
